Onset of Vitiligo Within Patients Receiving Immune Checkpoint Inhibitors: An Evidence-Based Review

Abstract

Keywords

adverse events CTLA-4 cutaneous immune checkpoint inhibitors melanoma PD-1 PD-L1 vitiligo

Get full access to this article

View all access options for this article.

References

Ezzedine

Eleftheriadou

Whitton

van Geel

Vitiligo. Lancet. 2015;386(9988):74-84.

Villadolid

Amin

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015;4(5):560-575.

Lacouture

Sibaud

Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(suppl 1):31-39.

Le Gal

Avril

Bosq

, et al. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol. 2001;117(6):1464-1470.

Hargadon

Johnson

Williams

CJ.

Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29-39.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.24 MB

1.16 MB